<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136058</url>
  </required_header>
  <id_info>
    <org_study_id>Hipfracture1</org_study_id>
    <secondary_id>AHFMR 200100791-2</secondary_id>
    <nct_id>NCT00136058</nct_id>
  </id_info>
  <brief_title>Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients</brief_title>
  <official_title>Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Heritage Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if an intervention with a fracture manager to&#xD;
      arrange bone densitometry after a hip fracture is more effective in diagnosing and treating&#xD;
      osteoporosis when compared to &quot;usual care&quot;. &quot;Usual care&quot; consists of no intervention to&#xD;
      arrange bone mineral density (BMD) testing or therapy other than what normally occurs in the&#xD;
      community. The investigators postulate that a fracture manager will be more effective in&#xD;
      getting BMD done and in starting appropriate therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All hip fracture patients in the Edmonton area will be screened for eligibility (mini-mental&#xD;
      status &gt;20, not on active osteoporosis pharmacologic therapy). All patients will have&#xD;
      informed consent obtained. Patients will be randomized to 2 groups:&#xD;
&#xD;
        -  Group 1: Active intervention. The fracture manager will arrange for bone densitometry&#xD;
           (DEXA) to be done 3-6 months after the fracture. If the patient meets standard criteria&#xD;
           for osteoporosis, therapy with a bisphosphonate (alendronate or risedronate) will be&#xD;
           instituted by the study physicians.&#xD;
&#xD;
        -  Group 2: Usual care. Patients will receive basic information about calcium and vitamin D&#xD;
           and osteoporosis and told to follow up with their family doctor. At 6 months, patients&#xD;
           will be contacted to determine if they have had a BMD done or started on active (drug)&#xD;
           osteoporosis therapy. If not, the fracture manager will arrange the BMD and if&#xD;
           appropriate therapy will be started by the study physicians.&#xD;
&#xD;
      All patients will be followed for 1 year. The primary endpoints are the number of patients&#xD;
      who get a BMD and the number who are started on active osteoporosis therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of patients who get a BMD and the number who are started on active osteoporosis therapy</measure>
  </primary_outcome>
  <enrollment>250</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone densitometry (DEXA)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate or risedronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 50 or over; males or females.&#xD;
&#xD;
          -  Reside in the community or have access to bone densitometry&#xD;
&#xD;
          -  Hip fracture&#xD;
&#xD;
          -  Patient can consent or proxy consent available&#xD;
&#xD;
          -  No contraindications to bisphosphonates&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refuses consent process&#xD;
&#xD;
          -  Already receiving active drug therapy for osteoporosis other than calcium and vitamin&#xD;
             D&#xD;
&#xD;
          -  Dementia or delirium&#xD;
&#xD;
          -  Pathological fracture&#xD;
&#xD;
          -  Chronic corticosteroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Morrish, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <keyword>osteoporosis</keyword>
  <keyword>hip fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

